News

PS-Fertility, maker of a male fertility test, to establish HQ outside Charlottesville

Life sciences startup PS-Fertility Inc. will invest $1.4 million to build out a headquarters and laboratory in Albemarle County, the office of Virginia Gov. Glenn Youngkin announced Wednesday.

PS-Fertility is aiming to commercialize a male fertility diagnostic that was originally developed at the University of Virginia. The company will lease 4,000 square feet at 3030 Vision Lane, just south of Charlottesville’s city limits, for its headquarters and lab as well as a test kit assembly operation, according to the announcement. PS-Fertility said it plans to create 31 new jobs with the project.

The company’s diagnostic tests for the presence of a biomarker on sperm cells necessary for fertilization, which can offer information on male fertility. PS-Fertility plans to use an at-home collection model, where samples are mailed to the new lab from across the country.

CEO Kevin Combs said in a statement his company planned to launch “in the very near future.”

The Virginia Economic Development Partnership said it worked with Albemarle County to secure the project for the state. Its Virginia Jobs Investment Program will support PS-Fertility’s hiring efforts by providing consultative services and funding to support recruitment and training.

“Virginia is the birthplace of innovations, and PS-Fertility’s groundbreaking discovery demonstrates the importance of our entrepreneurial ecosystems that lead to new technologies and products, ultimately resulting in new jobs,” Caren Merrick, Virginia’s secretary of commerce and trade, said in a statement.

Read more here.

Recent News

08/19/2026

ATCC Receives New CDC Award to Advance Influenza Testing and Surveillance

ATCC has been selected by the Centers for Disease Control and Prevention (CDC) for a new contract to support serological assays for the detection and characterization of influenza viruses. The award, valued at up to $7.3 million over the 5-year contract period (contract 75D30126C21030), will support CDC’s National Center for Immunization and Respiratory Diseases, Influenza

08/18/2026

Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients

08/14/2026

Transforming the finance function in life sciences: Empower scalable growth

Life sciences companies operate in one of the most complex business environments. Long R&D timelines, limited early-stage revenue, and dependence on external funding create a financial landscape where every decision carries strategic weight. In this context, finance is not a back-office function. It is an operational engine that drives whether a company survives, scales, or